pnb0408 dihexa Dihexa | 1401708-83-5

Protocols commonly use subcutaneous injection in a loading-then-maintenance pattern over 46 week blocks, but there is no FDA-approved product or official dosing

Others can reduce very gradually and slowly and still experience symptoms long after stopping

It is designed to be administered once weekly via a subcutaneous injection, and its primary purpose is the treatment of obesity and overweight

This is shown in Figure 1

To generate our tamoxifen-inducible Gdf11 knockout model, mice containing a floxed Gdf11 allele with loxP sites flanking exons 2 and 3 of Gdf11 [1] were bred with Tg(cre/Esr1)5Amc/J mice, obtained from Jackson labs (JAX no